Redeye comments on CLS’s rights issue outcome and adjusts our model accordingly.
Redeye comments on CLS’s rights issue announcement and updates its valuation of the company accordingly.
Redeye provides an update following CLS’s Q2 2026 report.
Redeye provides an update following CLS’s Q1 2026 report.
Redeye is positive about the large SEK23m order from ClearPoint Neuro, as we believe it provides much-needed confidence in CLS’s accelerated...
Redeye provides an update after CLS and ClearPoint reached a long-term agreement on the future ramp-up within the neurosurgery segment.
Redeye provides an update following CLS’s Q4 2025 report.
Redeye comments on the news that the TRANBERG Thermal Therapy System for focal laser ablation (FLA) has been installed at Andros Clinics in ...
Redeye provides an update following CLS’s Q3 2025 report.
Redeye is positive about the results from CLS’s study at Skåne University Hospital.
Redeye leaves a short comment on CLS’s fully subscribed warrants program (TO8B).
Redeye is positive about the FDA clearance to expand the labeling of the Prism system.
Redeye makes a correction to our estimates, slightly impacting our fair value range.
Redeye provides an update following CLS’s Q2 2025 report.
Redeye comments on the changes in CLS’s Board of Directors.
Redeye provides an update following CLS’s Q1 2025 report.
Redeye endorses CLS’s FDA submission to include 1.5 Tesla MRI guidance to the Prism system.
Redeye comments on the updated clinical guidelines regarding the use of LITT in patients with metastatic brain tumours and radiation necrosi...
Redeye comments on CLS’s directed issue, raising up to SEK37m.
Redeye provides an update following CLS’s Q4 2024 report.
Today, 13.00-13.45, Clinical Laserthermia Systems CEO Dan Mogren and CFO Håkan Rosqvist will present the company’s quarterly report, followe...
Redeye comments on CLS’s recap of 2024 and outlook for 2025-2026.
Redeye provides a note about CLS’s TO7B outcome.
Redeye provides an update following CLS’s Q3 2024 report.
Redeye provides a note about CLS’s decision to concentrate fully on its neurosurgery business.
Redeye provides a brief comment on the changes to CLS’ board of directors.
Redeye provides an update following CLS’ Q2 report that fairly aligned with our expectations and did not include any significant surprises.
Redeye provides an update as we resume our coverage after CLS’ rights issue.
Redeye briefly comments on CLS’ rights issue. We pause our coverage.
Redeye comments on CLS’ strategy change with an increased focus on the neurosurgery segment.
Redeye endorses that CLS’ partner, ClearPoint Neuro, has received FDA (510k) clearance for its Prism Bone Anchor Accessory.
Redeye updated its fair value range because of CLS’ reverse share split, where 200 existing shares have been consolidated into one share.
Redeye provides an update in relation to CLS’ Q4 2023 report.
Redeye comments on the TO6B outcome. With underwriting commitments, the TO6B was subscribed at 100%, meaning that CLS will receive approxima...
Redeye summarizes the highlights of CLS’ business update event.
Redeye endorses CLS’ market approval for its TRANBERG portfolio in Singapore.
Redeye endorses CLS’ new order of SEK8.1m from ClearPoint Neuro.
Redeye provides an update in relation to CLS’ Q3 2023 report.
Redeye endorses today’s announcement that CLS’ subsidiary CLS Americas has signed a Mobile Service Provider agreement with Kearney Urology C...
Redeye provides an update in relation to CLS’ Q2 2023 report.
Redeye shortly comments on CLS’ announcement regarding its directed offset issue to underwriters.
Redeye provides an update as we resume coverage after CLS’ rights issue.
Redeye is positive about CLS’ first mobile service provider agreement with AVANT Concierge Urology in Florida.
Redeye endorses the announcement that CLS and the US National Institutes of Health Clinical Center have initiated a research collaboration r...
Redeye comments on the outcome of warrants of series TO5B.
Redeye provides an update in relation to CLS’ Q4 2022 report.
Redeye endorses CLS’ partnership with the Dutch company Soteria Medical.
Redeye comments on CLS’ announcement that the company repays SEK3m of its loan with a directed share issue following lenders' request for lo...
Redeye provides an updated view of CLS after its Q3 2022 report and directed issue announcement.
Redeye endorses that CLS has received an order worth SEK5.
Redeye endorses that CLS has received FDA clearance for its MR-guided laser ablation system in neurosurgery.
Redeye comments on the outcome of CLS completed rights issue.
Redeye provides its comments on CLS Q2’22 report. The report did not include any surprises, and we believe the second half of the year will ...
Redeye provides its comments on CLS’ Q1’22 report. With ongoing discussions with potential new commercial partners in the urology segment, t...
Redeye comments on yesterday’s announcement regarding the outcome of CLS’ TO3 warrant programme.
Redeye is encouraged to learn that CLS’s TRANBERG Thermal Therapy System will be used by Focalyx Technologies, a developer of image-guided f...
Clinical Laserthermia Systems held a Strategy Update on the 24th of March.
Redeye comments on CLS’s Q4’21 report. We continue to see an interesting year ahead and reiterate our Base Case.
Redeye is encouraged to learn that Radboud University Medical Center in Nijmegen, the Netherlands, has initiated an Investigator Initiated T...
Redeye endorses CLS entering into a clinical trial agreement with Skåne University Hospital to evaluate MR-guided Laser Interstitial Thermal...
Redeye leaves its comments on CLS’s Q2 report and recent newsflow.
Redeye leaves a comment on CLS following today's update regarding its new sterilization supplier and the resumption of the prostate cancer s...
